Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.57 |
| ▸ | CNR2 | P34972 | 1/20 | 0.57 |
| ▸ | ACACB | O00763 | 1/20 | 0.55 |
| ▸ | FPR2 | P25090 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 10/20 | 0.51 |
| ▸ | ITGA4 | P13612 | 10/20 | 0.51 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.50 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1816209 | 0.84 | ACACB (0.53) | ACACBFPR2NPC1RAB9AITGB1 | |
| SCHEMBL1811166 | 0.82 | SMN1; SMN2 (0.55) | CNR1CNR2ACACBFPR2NPC1 | |
| SCHEMBL18607965 | 0.82 | ITGB1 (0.76) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL20387787 | 0.80 | PKM (0.54) | RAB9AITGB1ITGA4PSMB5 | |
| SCHEMBL19541999 | 0.78 | HPGD (0.45) | CNR1CNR2ITGB1ITGA4ITGA2 | |
| SCHEMBL12654827 | 0.78 | ACACB (0.50) | CNR1CNR2ACACBFPR2NPC1 | |
| SCHEMBL9893002 | 0.78 | ACACB (0.82) | ACACB | |
| SCHEMBL13452696 | 0.78 | NPC1 (0.59) | NPC1RAB9AITGB1ITGA4ITGA2 | |
| SCHEMBL12621261 | 0.77 | UTS2R (0.54) | ACACBFPR2NPC1RAB9AUTS2R | |
| SCHEMBL19541874 | 0.77 | NPC1 (0.54) | NPC1RAB9AITGB1ITGA4PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960350-B1 | NEW N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES | BAYER IP GMBH (DE) | 2015-08-19 | — | — | EP | disclosed |
| US-8314269-B2 | N-(1-methyl-2phenylethyl)benzamide derivatives | BAYER CROPSCIENCE AG (DE) | 2012-11-20 | — | — | US | disclosed |
| US-20110237678-A1 | N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2011-09-29 | — | — | US | disclosed |
| US-7951973-B2 | N-(1-methyl-2Phenylethyl)benzamide derivatives | BAYER CROPSCIENCE AG (DE) | 2011-05-31 | — | — | US | disclosed |
| US-7951973-B2 | N-(1-methyl-2Phenylethyl)benzamide derivatives | BAYER CROPSCIENCE AG (DE) | 2011-05-31 | — | — | US | disclosed |
| US-20090156682-A1 | N-(1-Methyl-2Phenylethyl)Benzamide Derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| EP-1960350-A1 | NEW N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007060162-A1 | NEW N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156682-A1 | N-(1-Methyl-2Phenylethyl)Benzamide Derivatives | CYP51A1, CYP1A2, CYP1A1 | CNR1 2980/4885CNR2 3023/4885ACACB 2344/4885 |
| US-20110237678-A1 | N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES | CYP51A1, CYP1A2, CYP1A1 | CNR1 3065/4885CNR2 3080/4885ACACB 2371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.